UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Best practice & research. Clinical haematology, ISSN 1521-6926, 03/2018, Volume 31, Issue 1, pp. 1 - 1
Journal Article
Blood, ISSN 0006-4971, 10/2019, Volume 134, Issue 16, pp. 1273 - 1274
Journal Article
Blood, ISSN 0006-4971, 04/2016, Volume 127, Issue 17, pp. 2055 - 2063
Life Sciences & Biomedicine | Hematology | Science & Technology | Translocation, Genetic | Lymphoma, Follicular - drug therapy | Prognosis | Humans | Neoplasm Proteins - physiology | Transcriptome | Tumor Microenvironment | Molecular Targeted Therapy | Lymphoma, Follicular - epidemiology | Lymphoma, Follicular - genetics | Neoplasm Proteins - genetics | B-Lymphocyte Subsets - pathology | Lymphoma, Follicular - pathology | Selection, Genetic | V(D)J Recombination | Treatment Outcome | Genes, bcl-2 | Tumor Burden | Randomized Controlled Trials as Topic | Rituximab - administration & dosage | B-Lymphocyte Subsets - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Models, Biological | Disease Management | Immunologic Factors - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 6, pp. 507 - 516
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Recurrence | Pyrazoles - therapeutic use | Administration, Oral | Humans | Middle Aged | Lymphoma, Mantle-Cell - drug therapy | Drug Resistance, Neoplasm | Male | Protein Kinase Inhibitors - adverse effects | Lymphoma, Mantle-Cell - mortality | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Pyrimidines - adverse effects | Survival Analysis | Aged, 80 and over | Lymphocyte Count | Adult | Female | Aged | Protein-Tyrosine Kinases - antagonists & inhibitors | Pyrazoles - adverse effects | Antimitotic agents | Relapse | Lymphomas | Product development | Drug therapy | Antineoplastic agents | Cancer | Tyrosine | Thrombocytopenia | Bortezomib | Statistical analysis | Diarrhea | Fatigue | Nausea | Non-Hodgkin's lymphoma | Bruton's tyrosine kinase | Patients | Lymphoma | Signal transduction | Lymphocytes B | Antitumor activity | Protein-tyrosine kinase | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Blood, ISSN 0006-4971, 09/2016, Volume 128, Issue 12, pp. 1540 - 1541
Journal Article
Critical reviews in oncology/hematology, ISSN 1040-8428, 2010, Volume 80, Issue 1, pp. 69 - 86
Hematology, Oncology and Palliative Medicine | Bortezomib | Flavopiridol | Bendamustine | Lenalidomide | Mantle cell lymphoma | Rituximab | Temsirolimus | Non-Hodgkin's lymphoma | Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Recurrence | Prognosis | Humans | Lymphoma, Mantle-Cell - drug therapy | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Enzyme Inhibitors - therapeutic use | Lymphoma, Mantle-Cell - mortality | Lymphoma, Mantle-Cell - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Angiogenesis Inhibitors - therapeutic use | Care and treatment | Biological products | Non-Hodgkin's lymphomas | Radiotherapy | Immunotherapy | Cancer | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 311 - 322
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Recurrence | Humans | Middle Aged | Male | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Antineoplastic Agents - administration & dosage | Remission Induction | Sulfonamides - pharmacokinetics | Dose-Response Relationship, Drug | Disease-Free Survival | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Antineoplastic Agents - adverse effects | Aged, 80 and over | Sulfonamides - adverse effects | Adult | Female | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Antineoplastic Agents - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics | Antimitotic agents | Treatment outcome | Care and treatment | Usage | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Dosage and administration | Antineoplastic agents | Pharmacokinetics | Risk factors | Flow cytometry | Chronic lymphatic leukemia | Cell survival | Leukemia | Minimal residual disease | Diarrhea | Chromosome deletion | Nausea | Lymphatic leukemia | Lymphoma | Patients | Proteins | Chemotherapy | Fludarabine | Clonal deletion | Lysis | Respiratory tract diseases | Chromosome 17 | Neutropenia | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Clinical advances in hematology & oncology, ISSN 1543-0790, 11/2018, Volume 16, Issue 11, pp. 732 - 734
Journal Article
Targeted oncology, ISSN 1776-2596, 6/2018, Volume 13, Issue 3, pp. 257 - 267
Journal Article
The New England journal of medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 11, pp. 1008 - 1018
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | General aspects | Medical sciences | Recurrence | Lymph Nodes - pathology | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents - therapeutic use | Lymphoma, Non-Hodgkin - pathology | Class Ia Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Disease-Free Survival | Neoplasm Grading | Antineoplastic Agents - adverse effects | Aged, 80 and over | Lymphocyte Count | Adult | Female | Aged | Lymphoma, Non-Hodgkin - mortality | Purines - adverse effects | Purines - therapeutic use | Quinazolinones - therapeutic use | Quinazolinones - adverse effects | Lymphoma, Non-Hodgkin - drug therapy | Phosphatidylinositol | Care and treatment | Lymphomas | Research | Medical research | Cell survival | Diarrhea | Rituximab | B-cell receptor | Non-Hodgkin's lymphoma | Kinases | Patients | Lymphoma | 1-Phosphatidylinositol 3-kinase | Chemotherapy | Lymphocytes B | Antitumor activity | Neutropenia | Macroglobulinemia | Index Medicus | Abridged Index Medicus
Journal Article
Best practice & research. Clinical haematology, ISSN 1521-6926, 09/2018, Volume 31, Issue 3, pp. 270 - 278
Clinical trials | Novel therapeutics | Mantle cell lymphoma | Life Sciences & Biomedicine | Hematology | Science & Technology | Bendamustine Hydrochloride - therapeutic use | Autografts | Cytarabine - therapeutic use | Humans | Lymphoma, Mantle-Cell - pathology | Neoplasm, Residual | Stem Cell Transplantation | Rituximab - therapeutic use | Lymphoma, Mantle-Cell - therapy | Maintenance Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Mantle-Cell - blood | Anthracyclines - therapeutic use | Medical colleges | Medical research | Chemotherapy | Anthracyclines | Comorbidity | Stem cells | Medicine, Experimental | Transplantation | Lymphomas | Cancer | Index Medicus
Journal Article